CompletedPHASE2, PHASE3NCT02143648
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Trevi Therapeutics
- Principal Investigator
- Chief Development OfficerTrevi Therapeutics
- Intervention
- nalbuphine HCl ER tablets 60 mg BID(drug)
- Enrollment
- 373 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2015
Study locations (30)
- Nephrology Associates PC, Birmingham, Alabama, United States
- University South Alabama Medical Center, Mobile, Alabama, United States
- Arizona Kidney Disease and Hypertension Center, Phoenix, Arizona, United States
- U.S. Renal Care Inc, Pine Bluff, Arkansas, United States
- North America Research Institute, Azusa, California, United States
- Pegasus Dialysis, LLC, Bakersfield, California, United States
- Central Nephrology Medical Group, Bakersfield, California, United States
- Academic Medical Research Institute, Los Angeles, California, United States
- Mark Lee MD, Inc, Whittier, California, United States
- Nephrology and Hypertension Associates PC, Middlebury, Connecticut, United States
- DaVita Inc Clinical Research Unit, Stamford, Connecticut, United States
- Nephrology Center DBA Paragon Health, Miami, Florida, United States
- Pines Clinical Research Inc, Pembroke Pines, Florida, United States
- Genesis Clinical Research, Tampa, Florida, United States
- DaVita Central Orlando Dialysis, Winter Park, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02143648 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.